REGN 250502 595.00P(REGN250502P595000) Stock Price Today

US OptionsDetailed Quotes

REGN250502P595000

Watchlist

0.55
-8.55-93.96%

15min DelayTrading May 2 10:52 ET

0.55High0.55Low

Intraday

5D
Daily

News

Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $810
Moomoo NewsMay 1 19:31 ET · Ratings
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Arguably The Most Innovative Biopharma Company I've Seen In The Last Two Decades'
Yahoo FinanceMay 1 15:40 ET
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
Yahoo FinanceMay 1 13:41 ET
Regeneron Pharma Is Maintained at Buy by Guggenheim
Dow JonesMay 1 10:58 ET · Ratings
Regeneron Pharma To Present New And Updated Data From Oncology And Hematology Portfolio At ASCO Annual Meeting
BenzingaMay 1 09:31 ET
Express News | Regeneron to Highlight Advances at Asco With Phase 3 Adjuvant Libtayo® (Cemiplimab) Cscc Updates and Promising Early Blood Cancer Data With Linvoseltamab Combination
ReutersMay 1 09:30 ET

Comments

Movers and Shakers

Apr 29 20:33

Columns Today's Pre-Market Movers and Top Ratings | SPOT, NVO, SOFI, and More

Morning Movers
Gapping Up
$Hims & Hers Health (HIMS.US)$ Hims & Hers surged 34.1% and $Novo-Nordisk A/S (NVO.US)$ increased by 4%. This followed Novo Nordisk's announcement that it will broaden the availability of its weight loss drug Wegovy by offering it through telehealth providers Hims & Hers Health, Ro, and Life MD, now that the drug is no longer facing shortages in the U.S.
$SoFi Technologies (SOFI.US)$ stock rose 5.9% after...

SoFi hits record revenue: Has the turnaround arrived?

Teddy123

Apr 21 12:27

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

$Regeneron Pharmaceuticals (REGN.US)$
Breakthrough: FDA Clears Dupixent for 300,000 Chronic Urticaria Patients After Decade-Long Wait

韭菜变主力

Mar 19 11:50

$Regeneron Pharmaceuticals (REGN.US)$ Sold my trading position at 734. Put a limit buy order at around 600 to wait for the gap fill. The 200 week moving average is a key resistance. The company has to prove the Eylea franchise revenue will not be significantly eroded by biosimilars.

Teddy123

Mar 10 12:26

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

$Regeneron Pharmaceuticals (REGN.US)$
Can Dupixent Transform Rare Skin Disease Treatment? New Trial Data Reveals Breakthrough

韭菜变主力

Mar 7 17:33

$Regeneron Pharmaceuticals (REGN.US)$ higher low?